Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Cebix (San Diego, CA), a clinical stage biotechnology company developing a modified insulin C-peptide for the treatment of complications associated with diabetes such as peripheral neuropathy, closed a $30.9M Series B financing. Participants were not identified.

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

Selecta Biosciences (Watertown, MA) a clinical-stage biopharmaceutical company focused on a new class of vaccines and immunotherapies for nicotine addiction, cancer, diabetes, influenza and human papilloma virus (HPV) closed a $47.25M Series D financing. Participants include Rusnano.

Catabasis Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on fatty acid conjugated compounds for severe hypertriglyceridemia, diabetes, inflammatory and metabolic diseases, closed a $8M Series A financing bringing total round to $47.6M. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

GenKyoTex (Switzerland) a clinical-stage pharmaceutical company focused on the treatment of complications of diabetes including diabetic nephropathy, closed a $20.8M Series C financing. Participants include Edmond de Rothschild Investment Partners, Vesalius Biocapital, MP Healthcare Venture Management and Specialized European Fund for Therapeutic Innovation.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.

Allostera Pharma (Canada) a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes, closed a $15.4M Series C financing. Participants include iNovia Capital, Genesys Capital, BDC Venture Capital and GO Capital.

« Previous Entries  Next Page »

to top of page...